COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): A multicenter, prospective, case-control study
The Lancet: Gastroenterology & Hepatology — Alexander JL, Kennedy NA, Ibraheim H, et al. | February 07, 2022
In view of the uncertainty concerning the effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination, researchers herein examined if patients with IBD on commonly used immunosuppressive drugs show altered COVID-19 vaccine-induced antibody responses.
In this multicenter, prospective, case-control study (VIP), a total of 483 participants were recruited, including patients with IBD being treated with thiopurines (n = 78), infliximab (n = 63), a thiopurine plus infliximab (n = 72), ustekinumab (n = 57), vedolizumab (n = 62), or tofacitinib (n = 30), and 121 healthy controls.
The primary analysis was performed including 370 participants without evidence of previous infection.
The immunogenicity of COVID-19 vaccines varies among patients with IBD according to immunosuppressive drug exposure, and is attenuated in recipients of infliximab, infliximab plus thiopurines, and tofacitinib.
On the basis of an individual's treatment, researchers suggest personalized scheduling of third primary, or booster, doses, and prioritization of patients taking anti-tumor necrosis factor and tofacitinib.